Gender-Affirming Hormone Therapy and Its Impact on Myocardial Mass and Cardiac Function, Heart, Liver and Pancreatic Fat Content

Launched by MEDICAL UNIVERSITY OF VIENNA · Feb 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the long-term effects of gender-affirming hormone therapy (GAHT) on various aspects of health, including heart function, body fat, and overall wellbeing. The researchers want to understand how this therapy impacts cardiovascular health, insulin levels, and psychological state over periods of 2, 5, and 10 years. By using advanced imaging techniques and blood tests, they aim to gather important data that hasn't been thoroughly explored in previous studies.

To participate in the trial, individuals must be transgender men or women who have been on GAHT for at least the past 2 years and have previously taken part in a pilot study. Participants will undergo a series of tests, including scans and questionnaires, to assess their health. It’s important to note that people under 18, those with certain medical devices, or those with specific health concerns like claustrophobia will not be eligible. This study is significant because it focuses on the mid- to long-term effects of GAHT, providing valuable insights that can help improve care for transgender individuals.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • participation in our pilot study
• • ongoing gender affirming hormone therapy during the last 2 years
• • willingness and competence to sign the informed consent form.
• Exclusion Criteria:
• • age \< 18 years
• • non-MRI conditional implants, grafts, and/or devices
• • non-MRI conditional tattoos
• • claustrophobia
• • current substance abuse
• • pregnancy
• • failure to comply with the study protocol and/or not following the instructions of the study team.